In 1989, a curious phenomenon was described: HIV-specific T-cell responses to the viral envelope and core proteins could be detected in antibody-positive and antigen-negative sexual partners of known HIV-positive men . Two other reports confirmed that initial observation on a total of six exposed seronegative (ESN) individuals, and the author raised the possibility that exposure to HIV that did not result in seroconversion and infection could be associated with the exclusive priming of T lymphocytes [2,3]. Analyses performed in different cohorts of individuals at high risk of HIV infection, including healthcare workers parenterally exposed to HIV and healthy newborns of HIV-infected mothers, revealed that HIV-specific CD4+ T helper cells, but not antibodies, were present in these persons [4,5]. These observations led to the hypothesis that viral exposure resulting in the exclusive priming of HIV-specific T cells could be associated with protection against the establishment of HIV infection .
This hypothesis was greatly strengthened by the independent observations that although the majority of commercial sex workers in Nairobi (the Pumwani cohort) became HIV-infected within a year, a sizable minority, subsequently estimated to be around 15% of the individuals tested, showed resistance to infection ; and that HIV-specific cytotoxic T lymphocytes (CTLs) could be isolated from healthy uninfected newborns of HIV-infected mothers . The novel concept of ‘resistance’ to HIV infection in HIV-exposed individuals was proposed, and the search for immune correlates of such protection against HIV infection was initiated at that point.
Subsequent pivotal reports showed that in HIV-exposed but uninfected individuals a particular genetic background, epitomized by the Δ32 deletion in the CCR5 receptor gene, can be detected , the production of soluble factors, including the CD8+ cell antiviral factor (CAF) and beta-chemokines, is increased [10–12], secretory HIV-specific IgA as well as T helper cells and CTLs can be observed in cervico-vaginal fluids and ejaculates [13,14], and natural killer (NK) cell activity is particularly potent . Thus, 15 years after the first description of the detection of HIV-specific T helper cells in seronegative individuals, the ‘immunologic advantage’ possibly conferring resistance to HIV infection can be summarized as being correlated with the elicitation of systemic and mucosal cell-mediated immunity, presumably within favorable genetic and innate immunity settings. The suggested multiple components of this ‘immunologic advantage’ are summarized in Fig. 1 and will be discussed in detail within this review.
Some methodological notes are needed: a consensus on how to define individuals with reduced susceptibility to HIV infection has not been reached. None of the definitions so far proposed is fully satisfactory. Thus, the definitions of ESN individuals and that of highly exposed persistently seronegatives overlook the possible presence of mucosal IgA in these individuals. The exposed uninfected and the multiple (or highly) exposed but uninfected definitions are based on the possibly erroneous assumption that these individuals have never undergone a subclinical and time-limited infection . Noticeably, there is not the final proof that the immune and genetic correlates described herein confer an absolute resistance to HIV infection; rather, we believe that these correlates are associated with a robust down-modulation of the susceptibility to such infection.
Lacking better definitions, the historic ESN acronym will be used in this review; we will define the immune and genetic correlates of this clinical state as associated with ‘reduced susceptibility’ to HIV infection. It should be noted, however, that the ESN individuals must not be confused with either long-term non-progressive (LTNP) patients, who have not developed AIDS for an extended period after HIV seroconversion, or with elite suppressors (or controllers), who show very low set-point viral load after acute infection. The latter groups are productively infected with HIV, whereas the HIV genome or proviruses are rarely, if ever, detectable in ESN individuals [2–5,7–13]. We will also concentrate on observations and studies conducted in humans. Notably, some of these observations are still controversial; the points that are still not fully clarified will be highlighted in the manuscript. Additionally, these studies are often based on small numbers of individuals, and reported results are sometimes almost anecdotic; we will summarize how many ESN individuals have been investigated to draw the main conclusions summarized herein. Finally, attempts to compare results obtained in different cohorts of ESN individuals have often limited success for a number of reasons, and in particular because a clear definition of who should be classified as lacking ESN. A clear definition of who should be classified as ESN is still required.
The small number of ESN individuals analyzed notwithstanding, the overall observations done on ESN individuals have allowed the creation of a quilt whose design is getting more and more complex, but from which a recognizable pattern is slowly emerging.
Immune correlates of reduced susceptibility to HIV infection: cell-mediated immunity
HIV-specific CD4+ T cell responses were initially described in heavily HIV-exposed but seronegative (ESN) men enrolled from the MACS cohort (n = 5/5) . These data were confirmed in other ESN groups including healthcare workers (n = 8/12) and healthy neonates born of HIV-infected mothers who did not receive antivirals (n = 8/23) [4,5]. HIV-specific CTLs in ESN individuals were first described some years later [8,16–19] in a dozen individuals. The lag was probably due to the fact that in the early 1990s, it was technically easier to measure CD4+ T cell than CTL responses.
CD4+ T cells
HIV-specific CD4+ T lymphocytes isolated from ESN individuals were found to produce interleukin (IL)-2 and to proliferate after stimulation with HIV peptides [20–22]. The HIV-specific T cells of ESN individuals were subsequently shown to produce low quantities of IL-10 in comparison with those from HIV-infected individuals . HIV envelope (env)-specific CD4+ T cells of ESN individuals were also shown to generate high levels of CC chemokines, in particular RANTES and MIP-1β [11,23] (RANTES observed in 9/12 ESN individuals enrolled; MIP-1β observed in 24/25 ESN individuals studied), and to be capable of suppressing in vitro the replication of macrophage-tropic HIV strains . Given the pivotal role of CC chemokines in modulating receptor binding and replication of HIV [24,25], these results are particularly important in connecting the ESN status and CD4+ T cell responses. Finally, higher levels of tumor necrosis factor (TNF)-α and TNF-β mRNA were detected in ESN individuals than in HIV-infected patients and healthy controls, both at the systemic level in peripheral blood lymphocytes and at the mucosal level in biopsies of the genital tract  (n = 9). No clear trends were identified regarding interferon (IFN)-γ production, as some groups reported that this cytokine is reduced [27–30] and other research indicated that IFN-γ is increased [12,31] in ESN individuals compared with HIV-infected individuals (Table 1). Notably, recent data suggested that HIV-specific T cell responses in ESN individuals could be dampened by an excess of regulatory T (Treg) cells. Consequently, the removal of CD4+CD25+ Treg revealed the presence of previously undetected strong HIV-specific T-cell responses in ESN newborns and neonates .
CD8+ T cells
HIV-specific CTLs have been described in several different ESN cohorts and many authors claim that these cells make a fundamental contribution to modulating resistance to HIV infection. HIV-specific CTLs have been observed and characterized in the Pumwani Kenyan cohort of sex workers both at systemic [19,36] and mucosal levels ; in injecting drug users [38,39]; and in sexual partners of HIV-infected patients [14,22,26]. These studies have analyzed a total of approximately 100 ESN individuals; HIV-specific CTLs were observed in the majority (>70%) of such ESN (Table 2).
The detection of HIV-specific CTLs in ESN individuals raises important scientific questions: only the successful infection of host cells, that is, infection resulting in at least one complete cycle of viral replication, allows the effective presentation of viral peptides within a binary complex with a human leukocyte antigen (HLA) class I molecule . The detection of HIV-specific CTLs in ESN individuals thus seems to indicate that HIV has managed to infect the host, but that its further propagation has been contained by immune mechanisms. The recent description of an alternative mechanism of processing and presentation by HLA class I molecules of exogenous antigens known as cross-priming could, nevertheless, explain the presence of CTLs in ESN individuals in the absence of actual infection. According to this mechanism, dendritic cells can process the virus and present it to CTL precursors in the absence of viral replication . If this is the case, the presence of HIV-specific CTLs in ESN individuals would be the consequence, not necessarily of an infection, but of a different and presumably more efficient processing pathway of HIV antigens within dendritic cells.
Comparison of HIV-specific T lymphocyte responses in ESN and HIV-infected individuals also suggests that the differences in susceptibility to HIV infection between these two groups resides in the quality rather than in the quantity of their immune responses. Thus, HIV-specific CD8+ CTLs of the ESN individuals recognize HIV epitopes that are different from those recognized by cells of HIV-infected patients ; rare conserved CD4+ T-cell epitopes within the HIV Env protein are immunodominant in ESN individuals, but are rarely recognized by HIV-infected patients ; and Gag-stimulated CD8+ T lymphocytes isolated from ESN individuals are characterized by higher levels of intracellular perforin and granzymes than those isolated from the HIV-infected partners  (n = 30 ESN individuals studied).
Role of continual exposure
The persistence of both HIV-specific CD4+ T cell and CTLs in ESN individuals seems to be strictly dependent on continuous virus exposure. In fact, various studies using different cohorts of ESN individuals that were followed longitudinally confirm that repeated exposure to HIV is necessary to maintain protective immunity. To summarize, HIV-specific CD4+ T cell and CTLs responses disappeared within 6–9 months after cessation of exposure to the virus in uninfected newborns of HIV-infected women  (n = 8/23) and in healthcare workers having reported a single professional exposure to HIV-infected body fluids  (n = 8/12); the concentration of HIV-specific IgA was significantly diminished in ESN women who underwent counseling and reported the adoption of safe-sex procedures  (n = 14/15); late seroconversion concomitant with the waning of HIV-specific CD8+ T cell responses occurred in two Kenyan HIV-resistant sex workers who interrupted commercial sex work for a period of time, probably due to reduced antigenic exposure ; and CD8+ cell non-cytotoxic responses (CNARs), observed in nearly half of 35 ESN individuals examined, were shown to decline in time after the last exposure to HIV . Subsequent reports also showed that both HIV-specific CD4+ T cell and CTL responses are more frequent in ESN women with more recent sexual exposure [26,40,46]; the magnitude of CD4+ T cell responses correlates with the frequency rather than with the duration of virus exposure in sex workers ; and an inverse correlation is detected between exposure to virus and in-vitro susceptibility of peripheral blood mononuclear cells (PBMCs) to HIV infection . These studies involved more than 100 ESN individuals recruited in different parts of the world.
The observation that maintenance of possibly protective HIV-specific immunity in both the systemic and mucosal compartments might be contingent upon repeated antigen-specific immune stimulation suggests that exposure to HIV does not result in the generation of long-lasting memory cells. It will be important to analyze this issue in depth. Available data on naive and memory T lymphocyte subpopulations in ESN individuals show the presence of a low naive/memory cell ratio: an observation that resembles what has been seen in HIV infection [33,34]. Additionally, Gag-specific central memory CD4+ and CD8+ T cells, as well as terminally differentiated CD8+ T cells were augmented, whereas CD8+ effector memory cells were found to be reduced in ESN individuals compared with HIV-infected individuals (studies performed in 15 ESN individuals). The increase in terminally differentiated lymphocytes was suggested to play a role in determining the resistant phenotype .
With few notable exceptions [47,48] (n = 45 and n = 20 ESN individuals analyzed, respectively), a consensus seems to emerge that indicates that ESN individuals are characterized by a generalized immune activation. This observation was made when CD4+/CD25+, CD8+/CD38+/CD45RO, and both HLADR-expressing CD4+ and CD8+ activated T lymphocytes, were analyzed in the peripheral blood of ESN individuals [26,34,49] and mucosally in commercial sex workers and their heterosexual partners  (a total of 93 individuals was investigated). It is also important to underline that recent results by Suy et al.  indicate that peripheral lymphocytes expressing CCR5 and CXCR4, the major HIV coreceptors, are upregulated on peripheral blood CD4+ T lymphocytes of sexually exposed ESN individuals (21 heterosexual couples were analyzed). Finally, some authors have also observed an increase of CD8+/CD28+ cells in ESN women . This finding is very intriguing, given that these cells produce CAF, a soluble factor considered to be responsible for the non-cytotoxic antiviral response exerted by CD8+ cells via the inhibition of HIV RNA transcription [50,51]. The expression of CAF has been previously described to be present in nearly half of 35 studied ESN individuals .
The observation that generalized immune activation, including an increase of lymphocytes bearing the major HIV coreceptors, might be associated with reduced susceptibility to HIV infection is curious given that T-cell activation facilitates spreading of HIV infection [52–54]. A plausible explanation could be that immune activation is a favorable factor in inducing an immune resistance to primary HIV infection in ESN individuals, whereas, during the course of HIV propagation, it facilitates the replication of the virus and the consequent progression of the disease.
Immune correlates of reduced susceptibility to HIV: humoral immunity
ESN individuals also display some unconventional humoral immune responses that may play a role in HIV neutralization: a very effective protective mechanism against viral infections. Two kinds of HIV-related humoral immune responses have been described in ESN individuals so far: antibodies to cellular proteins involved in the HIV infection/entry process, and HIV-specific mucosal antibodies.
The induction of anticell immune responses is rather common, and antilymphocyte antibodies have been observed early in sera from HIV-infected patients [55–57]. As the majority of these antibodies recognize HLA or CD4 molecules, their appearance had first been attributed to the cytopathic effect of HIV infection or to the long-lasting exposure to blood derivatives, as in the case of haemophiliacs [58,59]. In this regard, HIV-blocking IgG directed against HLA class I and CD4 molecules have been found in sera of ESN individuals [60–63] (n = 14/31). Anti-CD4 antibodies of ESN individuals recognize epitopes exposed by gp120 binding, suggesting that such antibody response is generated after repeated, long-lasting exposure to HIV in either horizontal or vertical transmission [61,63]. Although anti-CD4 antibodies were also found in some HIV-seropositive individuals and in some healthy blood donors, such anti-CD4 antibodies recognized epitopes different from those seen by antibodies found in sera of ESN individuals [61,62,64,65].
Another cellular protein, CCR5, is also targeted in ESN individuals by IgA and IgG antibodies at the mucosal and systemic levels. These antibodies are directed toward a conformational epitope corresponding to the second extracellular loop of CCR5 (YAAAQWDFGNTMCQ), which is not involved in HIV binding (6/48 ESN individuals analyzed). Thus, anti-CCR5 antibodies are likely to exert their possibly protective role through the downregulation of the CCR5 protein . The effect of anti-CCR5 antibodies could be due to the recognition and the interaction with specific epitopes or, alternatively, to steric hindrance. Recent data showing that the mechanism of action of these antibodies is mediated by the internalization of the receptor through a clathrin-dependent pathway  seem to suggest that CCR5-specific antibodies mediate their effect secondarily to epitope-specific recognition. Anti-CCR5 antibodies do not affect physiologic immune functions, due to the redundancy in chemokine receptor family, but could possibly play an initial role in protection . Notably, both anti-CD4 and anti-CCR5 antibodies have been described as specific markers of HIV-exposure in Asian and Caucasian but not in African ESN individuals  (anti-CCR5 and anti-CD4 antibodies were detected in 10.7 and 5.5% of the 149 enrolled ESN individuals, respectively). This discrepancy could be due to differences in the genetic background, in the route of exposure, or in the different environmental conditions, which can modulate immune responses to microbes [52,70–72].
The generation of anti-CCR5 antibodies has been attributed to several mechanisms: Ditzel et al.  showed that CCR5 can act as an alloantigen in CCR5Δ32 homozygous individuals. Anti-CCR5 antibodies directed toward epitopes different from those seen by antibodies of ESN individuals have been also observed in healthy individuals not previously exposed to HIV [74–76]. This finding could be explained by autoimmune phenomena triggered by membrane perturbations unrelated to HIV stimuli, such as exogenous or endogenous viruses or local inflammation. Alternatively, ESN individuals could have undergone priming with other (possibly cross-reactive) viruses or proteins, and once exposed to HIV, they could possibly mount a secondary response, directed toward allo-antigen and self-antigens associated with viral particles .
Allo-immune and auto-immune responses have been found in HIV-infected patients [58,61,78,79] and such potentially autoimmunity-associated immune responses could play a protective role in preventing HIV infection [75,80]. For instance, the HIV-neutralizing human monoclonal antibodies 2F5 and 4E10 are produced in natural infection, recognize conserved gp41 epitopes [80–82], and can bind membrane phospholipids with kinetics comparable with those of anticardiolipin immunoglobulins generated in autoimmune syndromes . The ability of these antibodies to bind cardiolipin has nevertheless recently been questioned by two independent groups [83,84]. These authors did not confirm the cardiolipin-binding properties of 2F5 and 4E10 and showed that, even if 4E10 can bind phospholipids, such binding has a much lower affinity compared with the one for gp41. These discrepancies seem to reflect technical difficulties that could be explained by a low affinity of the 2F5/4E10–phospholipid interaction or, alternatively, by the fact that the anionic lipids could be only a small portion of the antigen-binding paratope.
IgA antibodies are the most abundant isotypes found in mucosal secretions and epithelia and take part in several effector pathways that may protect the host from mucosal infection and clear the virus . Soluble antibodies can compete with HIV for attachment to epithelial cells , participate in opsonization, activate complement-mediated cell lysis, induce antibody-dependent cell-mediated cytotoxicity (ADCC) [86–88], and inhibit transcytosis [89,90]. As HIV is transmitted mainly by sexual intercourse and the genital mucosa is the main site where initial host–virus contact takes place, it is noteworthy that HIV-specific antibodies could be detected in the mucosa of African ESN individuals  (antibodies were detected in 7.5% of the 342 ESN individuals enrolled in the study). In this regard, IgA reactive to the above-mentioned conformational epitope of CCR5 in ESN individuals were able to specifically block transcytosis of HIV across a tight epithelial cell layer, but monoclonal antibodies against other regions of CCR5 had no effect on HIV-mediated transcytosis. This finding likely reflects a different conformation of CCR5 at the mucosal level [92,93].
Possible immune protection (or resistance) in ESN individuals has also correlated with HIV-specific mucosal IgA antibodies . These IgA have been observed in cervical secretions of ESN individuals from cohorts with different genetic background such as heterosexual women from Italy  (n = 16, IgA detected in the urine of 62% and in the cervical secretions of 81% of the enrolled ESN individuals) and India  (n = 40, IgA detected in 70% of individuals), as well as in female sex workers from Kenya [95,96] (two studies enrolled a total of 134 ESN individuals; IgA were observed in 76 and 74% of the two cohorts, respectively), Thailand  (n = 13, IgA detected in 76% of individuals); Cambodia  (n = 48, IgA detected in 39% of individuals); and Cote d'Ivoire  (n = 342, IgA detected in 7.3 and 29.8% of individuals using two different enzyme-linked immunosorbent assay (ELISA) methods]. These antibodies were also detected in the seminal fluid of male ESN partners of HIV-infected women  (n = 14, IgA detected in 78% of individuals). In addition, low levels of HIV-specific cervicovaginal IgG have also been found in female sexual partners of HIV-seropositive individuals with mixed ethnicity . Finally, recent results of a study analyzing 145 infants of HIV-infected mothers indicate that HIV-specific salivary IgA can be observed in such infants (IgA in 13/145 cases). Notably all HIV-exposed infants in whom IgA were detected remained uninfected after 1 year of follow-up .
The detection of HIV-reactive IgA in mucosal secretions of ESN individuals in the absence of detectable HIV-specific IgG in their sera (seronegativity) might seem enigmatic, especially from the conventional view of antibody class-switching. However, strong antiviral IgA responses with neutralizing activities have been observed in the absence of virus-specific IgM and IgG in experimental conditions. Thus, Sangster et al.  demonstrated a CD4+ T cell-dependent antiviral IgA response that is restricted exclusively to virus-specific B cells and is generated in the absence of B cell signaling via MHC class II or CD40. This phenomenon was observed in MHCII and CD40 knockout mice in which a reduction of virus-specific IgG and IgM, in the presence of strong virus-neutralizing IgA responses, could be detected. Recent experiments performed utilizing genetically modified mice have dissected the different molecular requirements for the induction of IgA and IgG antibody responses. In this latter study, Gärdby et al.  showed that differentiation to functional gut mucosal IgA responses against T-cell dependent antigens does not require signaling through CD28 and can be independent of germinal centers formations and isotype-switching in Peyer's patches. By contrast, serum IgA responses, similar to IgG responses, are dependent on germinal centers and CD28. Thus, they suggested a different costimulatory pathway response for the different immunoglobulin isotype. Moreover, costimulatory signals required for mucosal IgA responses are strikingly different from those for systemic antibody responses and conventional class-switching . In ESN individuals (n = 6), resistance to HIV infection has been associated with HIV-neutralizing antibodies directed to a small area within the α helical region of the extramembrane portion of gp41 (QARILAV epitope) . This interacts with the C5 region in gp120 , a conserved neutralizing determinant. It is noteworthy that the α helical region of gp41 is not recognized by IgA in HIV-infected individuals. In other ESN cohorts, HIV-neutralizing IgA recognize a separate immunodominant region of gp41 (ELDKWA epitope) , which is frequently recognized by HIV-seropositive individuals. Possibly more than one HIV region can modulate the host's susceptibility to HIV.
HIV-specific IgA of ESN individuals have been shown to prevent HIV entry into CD4+ T cells in in-vitro infection of PBMC [107,108] and to inhibit HIV transcytosis in an in-vitro model using colon cell lines [109,110]. IgA from ESN individuals were also shown to cross-neutralize primary HIV isolates from different clades (including A, B, C, and D clades)  (30 ESN individuals were analyzed overall). Finally, recent results showed that the saliva and breast milk concentration of CCL28, a chemokine that preferentially attracts IgA-secreting plasma cells in the epithelial lamina propria [111,112], is increased in the majority (78% of 50 individuals) of ESN individuals. A direct correlation between CCL28 and survival of HIV-infected and breastfed neonates was detected in a Zambian cohort . Notably, administration of mice with a CCL28-expressing construct resulted in a significant increase of IgA-secreting plasma cells in the rectal/genital mucosa  (Table 3).
An important caveat regarding these results is that mucosal IgA antibodies have been observed in some but not all groups of ESN individuals. Thus, studies performed in some cohorts of African and North American ESN individuals did not show mucosal HIV-specific IgA [114,115] (J. Mestecky et al., unpublished observations) (n = 97), whereas ambiguous results (IgA in 2/14 ESN individuals) were reported in another cohort . Such discrepancy could be due to technical difficulties associated with detection of IgA in mucosal fluids, which can have very low concentrations of such antibodies [116–118]. In addition, although secretory IgA are only partially sensitive to proteolytic cleavage , mucosal immunoglobulin levels can vary due to different collection methods and to the concentrations of proeolytic enzymes. Nevertheless, when specimens collected in multiple ESN cohorts with different methods were analyzed in the same laboratory using the same ELISA methodology and the same source of antigen, HIV-specific IgAs were detected in some but not all such cohorts (J. Mestecky et al., manuscript in preparation). These contradictory results suggest that currently unknown factors may be involved in induction and/or detection of HIV-specific mucosal immune responses. Finally, although mucosal HIV-specific antibodies might play a role in preventing horizontal HIV transmission at the mucosal level, it seems that these antibodies do not play any role in the prevention of infection transmitted through breast milk [120,121].
Innate immunity and the modulation of susceptibility to HIV infection
The role of innate immunity in the modulation of susceptibility to HIV infection is unclear and few reports describe a possible role for this arm of the immune response. The activation of NK cells in the early phase of lentiviral infections and the possible role of these cells in the containment of acute viral replication has been demonstrated in a monkey model of SIV infection . A similar inverse correlation between the CC chemokine-producing activities of host NK cells and levels of viremia in HIV infection has also been reported . Further, an increase in NK cell activity has been observed in 37 HIV-exposed but uninfected Vietnamese injecting drug users, suggesting a possible protective role of NK cells . It has also been shown that low numbers of NK cells are associated with rapid progression to AIDS in HIV-infected individuals . These results were confirmed by Jennes et al. , who also demonstrated that, although killer cell immunoglobulin-like receptors (KIRs) as a whole are expressed normally on NK cells of ESN individuals, HLA molecules that bind inhibitory KIR are downregulated in these individuals (n = 41). Further, a high KIR3DS1/KIR3DL1 ratio associated with downregulated KIR3DL1 transcript levels and an increased NKG2C/NKG2A ratio were detected in ESN individuals  (n = 80). The increased expression of the activating receptor KIR3DS1 was recently confirmed  (n = 25); these observations seem to support the notion that NK cell activity is indeed augmented in ESN individuals Finally, results of a very recent study that analyzed particular allele combinations in 46 ESN individuals showed that the coexpression of KIR3DL1*h/*y and B*57, which has been associated with a reduced risk of progressing to AIDS in HIV-infected individuals , also lowers the risk of infection in ESN individuals .
The possibility that innate mechanisms could play a role in protection against HIV infection was reinitiated by the exciting discovery of innate intracellular antiviral proteins. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like editing complex (APOBEC) proteins are the most important of these antiviral proteins. In particular, APOBEC3G shows a broad antiviral activity capable of reducing viral fitness. This is achieved by the introduction of by introducing detrimental levels of G-to-A hypermutations in the proviral genome, through the conversion of cytosine to uracil in the minus-sense single-strand DNA during reverse transcription. APOBEC3G can also prevent proviral integration into the cellular genome through a deamination-independent mechanism (review in ). The antiviral activity of human APOBEC3G is counteracted by the viral protein Vif; it could, therefore, be argued that the fate of exposure to HIV is determined by the relative balance between APOBEC3G and Vif. Recent results demonstrated that higher basal and IFN-α-induced APOBEC3G mRNA and protein levels are seen in monocyte/macrophage-lineage cells of ESN individuals  (n = 30). Other authors analyzed APOBEC3G in resting and activated CD4+ and CD8+ T cells of ESN individuals (n = 8) and found a slightly lower expression of APOBEC3G in resting CD4+ T cells ; these authors did not analyze monocyte/macrophage-lineage cells and focused on resting lymphocytes alone. Overall, these results seem to suggest that endogenous antiviral factors could play a role in determining susceptibility to HIV (Table 4).
Additional data obtained by a transcriptome and proteome analyses on T cells and plasma or sera of 21 ESN individuals indicated that several innate immune genes are upregulated in activated T cells of ESN individuals. In particular, IL-22, a cytokine that induces the production of acute-phase proteins, was significantly increased in ESN individuals compared with the values observed in either HIV-infected patients or healthy controls . Moreover, a higher quantity of the acute-phase amyloid A protein (A-SAA) was present in sera of ESN individuals. These high levels of A-SAA were shown to have an inhibitory activity on the in-vitro infection of dendritic cells by HIV . This observation can probably be explained by binding of A-SAA to its formyl peptide receptor on the dendritic cell surface, which, in turn, mediates CCR5 phosphorylation and downregulation. Because IL-22 upregulates the production of acute-phase proteins, and in particular of A-SAA, these data suggest that an IL-22-induced pathway of protein production could contribute to reducing susceptibility to HIV infection. Subsequent experiments also indicated that the IL-22-mediated antiviral effects include the stimulation of the production of beta-defensins 2 and 3 by ectocervix epithelial cells as well (F. Veas, M. Clerici, unpublished observations). These innate cationic peptides have broad antiviral activities directed against a wide spectrum of viruses including HIV (for a recent review see ) and might play a role in the generation of the ESN status .
Genetic correlates of reduced susceptibility to HIV infection
Host genetic factors can confer resistance to HIV acquisition at different steps in viral infection including the penetration of the virions through surface barriers of the body, their attachment to target cells, integration, and viral gene expression. In addition, host genetic factors also influence immune responses to HIV antigens. The molecularly best defined genetic factor that confers cellular resistance to HIV infection is the homozygous 32 base-pair deletion in the CCR5 chemokine receptor gene (the CCR5Δ32 allele), which results in the lack of cell-surface expression of the coreceptor for macrophage-tropic HIV. Homozygosity for this mutation was first observed in two uninfected individuals with histories of multiple high-risk sexual exposure to HIV ; subsequent analyses of multiple cohorts have nevertheless revealed very low frequencies (1.7–12%) of CCR5Δ32 homozygosity. These findings indicate the possible importance of other genetic factors (reviewed in ) (Table 4). Polymorphisms in the regulatory region of the CCR5 gene have been identified, but no significant association of a particular genotype with HIV-exposed but uninfected status has been observed [134,135]. A genetic variant of CCR2 with a valine-to-isoleucine change at position 64 (CCR2-64I) is in strong linkage disequilibrium with a mutation in the CCR5 regulatory region . There are discrepant reports as to the possible association of this genotype with a reduced risk of HIV acquisition [137,138]. Similarly, an A-to-G substitution at position 801 within the 3′ untranslated region of the SDF-1 chemokine gene was reported to be highly accumulated among a group of high-risk exposed uninfected individuals . However, this genotype was not associated with resistance to HIV acquisition in separate studies .
Mannose-binding lectin (MBL) is a component of the soluble innate immune complement system and can bind HIV as well as surface oligosaccharides of other infectious microorganisms. Variant alleles of the MBL gene have been associated with susceptibility to HIV infection in Danish  (n = 96) and Gabonese  (n = 188) cohorts, but the frequencies of the variant are very low, and no association was observed in a Columbian cohort  (n = 278). Likewise, dendritic cells are among the first cell types to encounter HIV during sexual transmission, and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) is involved in the CD4-independent binding of HIV gp120. A deletion in the 23 amino acid repeat units within the neck region of DC-SIGN was noted at higher frequency among ESN individuals in one cohort , but the reported frequency of the variant alleles was low (3.2%), and cannot account for the majority of the uninfected phenotype. DC-SIGN and its homologue DC-SIGNR (DC-SIGN related) play a crucial role in enhancing trans-infection of CD4+ T cells from HIV-carrying dendritic cells in the regional lymph nodes. A haplotype consisting of a specific repeat number in exon 4 and a SNP allele in exon 5 of the DC-SIGNR gene has also been associated with the ESN status among 102 HIV-seronegative individuals of HIV-seropositive spouses in Thailand . Variants of the human natural resistance-associated macrophage protein 1 were also associated with a reduced risk of HIV acquisition, but were not studied in exposed uninfected individuals .
Vitamin D receptor gene sequence variations and polymorphisms in the transcriptional regulator gene interferon regulatory factor 1 (IRF-1) have recently been shown to correlate with reduced susceptibility to HIV infection  in ESN individuals (n = 125). These results are particularly important considering that vitamin D acts as an immunoregulatory hormone by activating monocytes and stimulating cell-mediated immunity. The observation that the protective IRF-1 genotypes are associated with significantly lower basal IRF-1 expression and reduced responsiveness to exogenous IFN-γ stimulation  seems to suggest that the increased production of IFN-γ has a marginal role or might be an epiphenomenon in the modulation of susceptibility to HIV infection. Finally, recent results focusing on the gene encoding CCL3L1, a natural ligand for the HIV coreceptor CCR5 with a suppressive effect on HIV replication, showed, in a large cohort of individuals, that a CCL3L1 copy number lower than the population average is associated with markedly enhanced rates of HIV infection and AIDS development [145,146]. Additional results obtained in a large cohort (n = 849) of HIV-infected South African pregnant women indicated that higher CCL3L1 copy number is associated with reduced vertical HIV transmission . Finally, a study performed in human T lymphotropic virus-2-infected individuals showed that the median copy number of the CCL3L1 and the CCL3L1/CCL3 mRNA ratios were increased in ESN individuals and in LTNP patients compared to those in healthy controls  (n = 8).
Immune responses to viral antigens are strictly controlled by host immune response genes. Major histocompatibility complex (MHC) genes are by far the most influential of such genes due to their function in binding and presenting antigenic epitopes to T lymphocytes. Effects of different MHC alleles on spontaneous and vaccine-induced immune resistance against fatal retroviral infection have been studied in detail using the mouse model of immunosuppressive Friend retrovirus infection [158–160]. Effects of human MHC genotypes on host immune responses to HIV have been recognized (reviewed in [161,162]): HLA-B*57 is associated with particularly effective CTLs responses and lower viral load, B*27 is involved in selective presentation of an immunodominant p24gag epitope, and B*35 is most consistently associated with an earlier AIDS progression among whites.
Associations of particular HLA class II alleles and resistance to HIV acquisition have been reported (reviewed in [158–162]). In this regard, a study performed in the Pumwani Sex Worker cohort revealed that several DQB1 alleles are associated with resistance to HIV infection . Additionally, studies performed in HIV-infected mothers showed that class I HLA concordance between mother and infant was independently associated with a stepwise increase in the risk of perinatal HIV transmission, suggesting that discordant HLA provide infants with a means of protection against HIV, possibly as a result of allogeneic infant antimaternal MHC immune responses .
Non-MHC genes are involved also in the regulation of host immune responses, the best documented example being the Rfv3 locus described for Friend mouse retroviral infection [163,164]. Rfv3 genotypes influence the duration of Friend virus viremia in mice after infection and this effect is mediated through the Rfv3 gene's influence on the production of virus-neutralizing antibodies [164,165]. A recent study has indicated that a gene located within a segment of human chromosome 22 that is autologous to the region of mouse chromosome 15 that harbors the Rfv3 locus is strongly associated with resistance to HIV acquisition  (n = 42) (Table 4). It is of particular interest that the APOBEC3 locus is present in the middle of the above chromosomal segment . Notably, very recent data indicate that polymorphisms in the APOBEC3 locus indeed affect the susceptibility to Friend virus infection in mice , and that Rfv3 is encoded by APOBEC .
What emerges from this review of immunologic analyses performed over several years in different cohorts of ESN individuals is that, paradoxically and with few exceptions (e.g., immune activation), the ‘immunologic advantage’ of ESN individuals stems from their ability to react to HIV in a normal, physiological way. Challenged with a virus, the immune system of ESN individuals responds with the activation of multiple effector mechanisms, which are the same mechanisms normally triggered in response to viruses. The difference that makes the immune response to HIV of ESN individuals stand apart is the absence of an effective memory function. What creates the ‘immune advantage’ of ESN individuals? A number of speculations are possible: ESN individuals handle HIV in the same way as they would handle any other viruses, that is, the immune system of ESN individuals does not recognize the biological peculiarities of HIV that render HIV infection a chronic process; genetic differences stimulate the activation of slightly peculiar immune responses; stronger/better immune effector mechanisms are present in ESN individuals. Fifteen years ago, it was theorized that TH1 responses and CMI could be particularly intense in ESN individuals, and that these immunologic features would lead to protection [168,169]. If genetic factors could be identified that result in the activation of stronger/better TH1 responses and CMI, possibly in association with innate and mucosal immunity, the loop could be closed.
How can we use this body of knowledge to design a vaccine? An indispensable premise is that LTNP patients, the focus of many sophisticated analyses, are not ESN individuals. LTNP patients are extremely interesting HIV-infected patients, and results of in-depth analyses on these individuals are likely to shed light on the pathogenesis of HIV disease. Nevertheless, although LTNP patients, despite being able to avoid progression to AIDS for an extended period of time, are indeed infected, ESN individuals are not infected. It appears that the identification of the immune/genetic correlates in ESN individuals alone could clarify how to design preventive vaccine approaches. Another fundamental point is that any vaccine approach will have to include the triggering of a potent innate immune response. The results obtained in ESN individuals, and brute logic, indicate that it is very likely that without this component effective defense against HIV – a defense that will prevent the integration of viral genome into the host cell – will be nearly impossible to achieve. Unfortunately, we know much better how to manipulate acquired immunity than we do to innate immunity.
With all these possibilities considered, the data summarized here suggest that an effective preventive vaccine needs to block the transmission of HIV particularly through the mucosal surface. This result would allow the penetration of only small quantities of HIV into the lymph-nodes/peripheral blood. Innate and specific immune responses, including CTLs and CNAR/chemokines would be capable of handling the reduction in this HIV load, preventing established infection .
How to stimulate these responses? Vaccine constructs could include IFN-α, a cytokine with the ability to stimulate APOBEC, adjuvants/chemokines (IL-5, transforming growth factor-β, CCL28) to stimulate IgA-mediated mucosal immune responses, and adjuvant/cytokines (IL-7, IL-15), with the ability to elicit the generation of memory lymphocytes (Fig. 2). It will be important to verify whether this type of approach will be able to reproduce the ‘immunologic advantage’ that characterizes ESN individuals in the population at-large, possibly resulting in a true protection against HIV infection.
This study was supported by grants from the Istituto Superiore di Sanita' ‘Programma Nazionale di Ricerca sull’ AIDS'; the EMPRO and AVIP EC WP6 Projects; the nGIN WP7 Project; Tuscany Region, DG Right to Health and Solidarity Policy; the Japan Health Science Foundation; The Naito Foundation; 2007 Ricerca Finalizzata [Italian Ministry of Health]; 2007 Ricerca Corrente [Italian Ministry of Health; Progetto FIRB RETI, Rete Italiana Chimica Farmaceutica CHEM-PROFARMA-NET [RBPR05NWWC]; NIAID Grant 1 U19 AI062150; SIDACTION, CNRS & IRD; France.
The Exposed Seronegative study group
Luca Piacentini, Valentina Naddeo, Claudo Fenizia, Mara Biasin, Antonella Marino, Manuela Borelli, Eleonora Castelletti, Michela Pacei, Daria Trabattoni: Chair of Immunology, University of Milano, Milan, Italy.
Marina Saresella, Laboratory of Molecular Medicine and Biotechnology, Don C. Gnocchi Foundation IRCCS, Milan, Italy.
Claudia Pastori, Lorenzo Diomede, Chiara Alberti, Alice Parri: Immunobiology of HIV Unit, San Raffaele Scientific Institute, Milan, Italy.
Francesca Vichi, Piera Pierotti, Nadia Ferri, Sonia Parivir, Landini Licia, Lucia Franchi, Eugenio Cacace, Marco Poli, Silvia Scacciati: Infectious Disease Unit S. M. Annunziata Hospital Flirenze, Italy.
Johanna Gajardo, Gregor Dubois, Alexandra Fournet, Ilias Stefas: Institut de Recherche pour le Développement and University Montpellier 1, Viral & Molecular Immuno-Physiopathology Lab; Faculty of Pharmacy, Montpellier, France.
Yasuyoshi Kanari, Sachiyo Tsuji-Kawahara, Mayumi Sakamoto, and Eri Takeda: Department of Immunology, Kinki University School of Medicine, Osaka, Japan.
Masaaki Miyazawa reviewed the literature on genetic correlates of resistance and wrote this part of the manuscript.
Lucia Lopalco reviewed the literature on humoral immunity and wrote this part of the manuscript.
Francesco Mazzotta and Sergio Lo Caputo are responsible of the clinical coordination of the ESN cohorts that are at the basis of the ESN study group.
Francisco Veas reviewed the literature on innate immunity and wrote this part of the manuscript.
Mario Clerici reviewed the literature on cellular immunity, wrote, organized, edited, and finalized the whole manuscript.
1. Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, Lahdevirta J, et al. T cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV exposed sexual partners. AIDS 1989; 3:63–69.
2. Clerici M, Berzofsky JA, Shearer GM, Tackett CO. HIV-1 exposure indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J Infect Dis 1991; 164:178–182.
3. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992; 165:1012–1019.
4. Clerici M, Sison AV, Berzofsky JA, Rakusan TA, Brandt CD, Ellaurie M, et al. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS 1993; 7:1427–1435.
5. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, et al. HIV-specific T-helper activity in HIV seronegative healthcare workers accidentally exposed to HIV-contaminated blood. JAMA 1994; 271:42–46.
6. Shearer GM, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996; 7:21–24.
7. Fowke KR, Nagelkerke NJD, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348:1347–1351.
8. Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993; 341:860–861.
9. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367–377.
10. Stranford SA, Skurnick J, Louria D, Osmond D, Chang SY, Sninsky J, et al. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci U S A 1999; 96:1030–1035.
11. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Quillent C, et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 1997; 186:455–460.
12. Levy JA, Hsueh F, Blackbourn DJ, Wara D, Weintrub PS. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children. J Infect Dis 1998; 177:470–472.
13. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997; 3:1250–1257.
14. Lo Caputo S, Trabattoni D, Vichi F, Piconi S, Lopalco L, Villa ML, et al. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 2003; 17:531–539.
15. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171:5663–5667.
16. De Maria A, Cirillo C, Moretta L. Occurrence of HIV-1 specific cytolytic T cell activity in apparently uninfected children born to HIV-1 infected mothers. J Infect Dis 1994; 170:1296–1303.
17. Langlade-Demoyen P, Ngo-Giang-Huong F, Ferchal F. Oksenhendler E. HIV-nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV infected patients. J Clin Invest 1994; 93:1297–1307.
18. Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative healthcare workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995; 96:867–876.
19. Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998; 102:1758–1765.
20. Kelker HC, Seidlin M, Vogler M, Valentine FT. Lymphocytes from some long-term seronegative heterosexual partners of HIV-infected individuals proliferate in response to HIV antigens. AIDS Res Hum Retroviruses 1992; 8:1355–1359.
21. Goh WC, Markee J, Akridge RE, Meldorf M, Musey L, Karchmer T, et al. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999; 179:548–557.
22. Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, et al. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis 2002; 185:428–438.
23. Suresh P, Wanchu A, Bhatnagar A, Sachdeva RK, Sharma M. Spontaneous and antigen-induced chemokine production in exposed but uninfected partners of HIV type 1-infected individuals in North India. AIDS Res Hum Retroviruses 2007; 23:261–268.
24. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811–1815.
25. Gallo RC, Garzino-Demo A, DeVico AL. HIV infection and pathogenesis: what about chemokines? J Clin Immunol 1999; 19:293–299.
26. Biasin M, Caputo SL, Speciale L, Colombo F, Racioppi L, Zagliani A, et al. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis 2000; 182:1365–1374.
27. Promadej N, Costello C, Wernett MM, Kulkarni PS, Robison VA, Nelson KE, et al. Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. J Infect Dis 2003; 187:1053–1063.
28. Jennes W, Vuylsteke B, Borget MY, Traore-Ettiegne V, Maurice C, Nolan M, et al. HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'Ivoire. J Infect Dis 2004; 189:602–610.
29. Kebba A, Kaleebu P, Rowland S, Ingram R, Whitworth J, Imami N, et al. Distinct patterns of peripheral HIV-1-specific interferon-gamma responses in exposed HIV-1-seronegative individuals. J Infect Dis 2004; 189:1705–1713.
30. Hladik F, Desbien A, Lang J, Wang L, Ding Y, Holte S, et al. Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells. J Immunol 2003; 171:2671–2683.
31. Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006; 120:138–146.
32. Jennes W, Sawadogo S, Koblavi-Deme S, Vuylsteke B, Maurice C, Roels TH, et al. Cellular human immunodeficiency virus (HIV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Cote d'Ivoire. J Infect Dis 2003; 187:206–214.
33. Schenal M, Lo Caputo S, Fasano F, Vichi F, Saresella M, Pierotti P, et al. Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients. AIDS 2005; 19:653–661.
34. Tran HK, Chartier L, Troung LX, Nguyen NN, Fontanet A, Barre-Sinoussi FE, et al. Systemic immune activation in HIV-1-exposed uninfected Vietnamese intravascular drug users. AIDS Res Hum Retrovir 2006; 22:255–261.
35. Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, et al. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS ONE 2006; 1:e102. doi: 10.1371/journal.pone.0000102.
36. Alimonti JB, Kimani J, Matu L, Wachihi C, Kaul R, Plummer FA, et al. Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol Cell Biol 2006; 84:482–485.
37. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, Njagi E, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000; 164:1602–1611.
38. Makedonas G, Bruneau J, Lin H, Sekaly RP, Lamothe F, Bernard NF. HIV-specific CD8+ T-cell activity in uninfected injection drug users is associated with maintenance of seronegativity. AIDS 2002; 16:1595–1602.
39. John R, Arango-Jaramillo S, Finny GJ, Schwartz DH. Risk associated HIV-1 cross-clade resistance of whole peripheral blood mononuclear cells from exposed uninfected individuals with wild-type CCR5. J Acquir Immune Defic Syndr 2004; 35:1–8.
40. Pallikkuth S, Wanchu A, Bhatnagar A, Sachdeva RK, Sharma M. Human immunodeficiency virus (HIV) gag antigen-specific T-helper and granule-dependent CD8 T-cell activities in exposed but uninfected heterosexual partners of HIV type 1-infected individuals in North India. Clin Vaccine Immunol 2007; 14:1196–1202.
41. Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of class I-presented antigens. Adv Immunol 2002; 80:1–70.
42. Reimann J, Schirmbeck R. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol Rev 1999; 172:131–152.
43. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, et al. CD8+ lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107:1303–1310.
44. Mazzoli S, Lopalco L, Salvi A, Trabattoni D, Lo Caputo S, Semplici F, et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999; 180:871–875.
45. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite preexisting HIV-specific CD8+ responses. J Clin Invest 2001; 107:341–349.
46. Bernard NF, Yannakis CM, Lee JS, Tsoukas CM. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. J Infect Dis 1999; 179:538–547.
47. Bègaud E, Chartier L, Marechal V, Ipero J, Leal J, Versmisse P, et al. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology 2006; 3:35.
48. Jennes W, Evertse D, Borget MY, Vuylsteke B, Maurice C, Nkengasong JN, et al. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin Exp Immunol 2006; 143:435–444.
49. Suy A, Castro P, Nomdedeu M, García F, López A, Fumero E, et al. Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis 2007; 196:1191–1201.
50. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1996; 17:217–224.
51. Levy JA. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 2003; 24:628–632.
52. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995; 16:187–191.
53. Shapira-Nahor O, Kalinkovich A, Weisman Z, Greenberg Z, Nahmias J, Shapiro M, et al. Increased susceptibility to HIV-1 infection of peripheral blood mononuclear cells from chronically immune-activated individuals. AIDS 1998; 12:1731–1733.
54. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, Kityo C, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 2005; 191:694–701.
55. Dorsett B, Cronin W, Chuma V, Ioachim HL. Antilymphocyte antibodies in patients with the acquired immune deficiency syndrome. Am J Medicine 1985; 78:621–626.
56. Daniel V, Schimpf K, Opelz G. Lymphocyte autoantibodies and alloantibodies in HIV-positive haemophilia patients. Clin Exp Immunol 1989; 75:178–183.
57. Borghi MO, De Santis C, Barcellini W, Lopalco L, Fain C, et al. Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients. J AIDS 1993; 6:1114–1119.
58. Blanton M, Balakrishnan K, Dumaswala U, Zelenski K, Greenwalt TJ. HLA antibodies in blood donors with reactive screening tests for antibody to the immunodeficiency virus. Transfusion 1987; 27:118–119.
59. Riera NE, Galassi N, de la Barrera S, Rickard E, Muchinik G, Perez-Bianco R, de Bracco MM. Antileukocyte antibodies as a consequence of HIV infection in HIV+ individuals. Immunol Lett 1992; 33:99–104.
60. Beretta A, Weiss SH, Rappocciolo G, Mayur R, De Santis C, Quirinale J, et al. Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis 1996; 173:472–476.
61. Burastero SE, Gaffi D, Lopalco L, Tambussi G, Borgonovo B, De Santis C, et al. Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. AIDS Res Hum Retrovir 1996; 12:273–280.
62. Lopalco L, Pastori C, Cosma A, Burastero SE, Capiluppi B, Boeri E, et al. Anticell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retrovir 2000; 16:109–115.
63. Lopalco L, Magnani Z, Confetti C, Brianza M, Saracco A, Ferraris G, et al. Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. AIDS Res Hum Retrovir 1999; 15:1079–1085.
64. Callahan LN, Roderiquez G, Mallinson M, Norcross MA. Analysis of HIV-induced autoantibodies to cryptic epitopes on human CD4. J Immunol 1992; 149:2194–2202.
65. Furci L, Beretta A, Siccardi A, Lazzarin A, Confetti C, Magnani Z, et al. Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects. AIDS Res Hum Retrovir 1997; 13:1461–1469.
66. Lopalco L, Barassi C, Pastori C, Longhi R, Burastero SE, Tambussi G, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol 2000; 164:3426–3433.
67. Pastori C, Weiser B, Barassi C, Uberti-Foppa C, Ghezzi S, Longhi R, et al. CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression. Blood 2006; 107:4825–4833.
68. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat Rev Microbiol 2006; 4:313–318.
69. Lopalco L, Barassi C, Paolucci C, Breda D, Brunelli D, Nguyen M, et al. Predictive value of anticell and antihuman immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol 2005; 86:339–348.
70. Rizzardini G, Piconi S, Ruzzante S, Fusi ML, Lukwiya M, Declich S, et al. Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS 1996; 10:1535–1542.
71. Rizzardini G, Trabattoni D, Saresella M, Piconi S, Lukwiya M, Declich S, et al. Immune activation in HIV-infected African individuals. Italian–Ugandan AIDS cooperation program. AIDS 1998; 12:2387–2396.
72. Clerici M, Butto S, Lukwiya M, Saresella M, Declich S, Trabattoni D, et al. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS 2000; 14:2083–2092.
73. Ditzel HJ, Rosenkilde MM, Garred P, Wang M, Koefoed K, Pedersen C, et al. The CCR5 receptor acts as an alloantigen in CCR5 Delta32 homozygous individuals: identification of chemokine and HIV-1-blocking human antibodies. Proc Natl Acad Sci U S A 1998; 95:5241–5245.
74. Bouhlal H, Hocini H, Quillent-Gregoire C, Donkova V, Rose S, Amara A, et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001; 166:7606–7611.
75. Bouhlal H, Latry V, Requena M, Aubry S, Kaveri SV, Kazatchkine MD, et al. Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J Immunol 2005; 174:7202–7209.
76. Eslahpazir J, Jenabian M, Bouhlal H, Hocini H, Carbonneil C, Gresenguet G, et al. Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clin Vacc Immunol 2008; 15:872–874.
77. Russo S, Lopalco L. Is autoimmunity a component of natural immunity to HIV? Curr HIV Res 2006; 4:177–190.
78. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1:329–337.
79. de Santis C, Lopalco L, Robbioni P, Longhi R, Rappocciolo G, Siccardi AG, Beretta A. Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. AIDS Res Hum Retrovir 1994; 10:157–162.
80. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906–1908.
81. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007; 178:4424–4435.
82. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: an hypothesis. Hum Antibodies 2005; 14:59–67.
83. Vcelar B, Stiegler G, Wolf HM, Muntean W, Leschnik B, Mehandru S, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007; 21:2161–2170.
84. Scherer EM, Zwick MB, Teyton L, Burton DR. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 2007; 21:2131–2139.
85. Kozlowski PA, Neutra MR. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003; 3:217–228.
86. Outlaw MC, Armstrong SJ, Dimmock NJ. Mechanisms of neutralization of influenza virus in tracheal epithelial and BHK cells vary according to IgG concentration. Virology 1990; 178:478–485.
87. Robert-Guroff M. IgG surfaces as an important component in mucosal protection. Nat Med 2000; 6:129–130.
88. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996; 272:104–107.
89. Krause RM, Dimmock NJ, Morens DM. Summary of antibody workshop: the role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J Infect Dis 1997; 176:549–559.
90. van Egmond M, Damen CA, van Spriel AB, Vidarsson G, van Garderen E, van de Winkel JG. IgA and the IgA Fc receptor. Trends Immunol 2001; 22:205–211.
91. Belec L, Ghys PD, Hocini H, Nkengasong JN, Tranchot-Diallo J, Diallo MO, et al. Cervicovaginal secretory antibodies to HIV type 1 that block viral transcytosis through epithelial barriers in highly exposed HIV-1- seronegative African women. J Infect Dis 2001; 184:1412–1422.
92. Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C, Desgranges C. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti HIV envelope protein dIgA or IgM. Immunity 1998; 9:277–287.
93. Barassi C, Lazzarin A, Lopalco L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood 2004; 104:2205–2206.
94. Wanchu A, Sachdev R, Bagga R. HIV-1 gag-specific mucosal antibodies in a cohort of exposed but uninfected heterosexual partners of HIV-1-infected Individuals in north India. CROI 2008; Boston, MA, USA; 3–6 February 2008, abstract 430.
95. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliana A, Mwangi FM, et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999; 13:23–29.
96. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, et al. HIV-neutralizing IgA and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008; 22:727–735.
97. Beyrer C, Artenstein AW, Rugpao S, Stephens H, VanCott TC, Robb ML, et al. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. J Infect Dis 1999; 179:59–67.
98. Nguyen M, Pean P, Lopalco L, Nouhin J, Phoung V, Ing R, et al. HIV specific antibodies but not T cell responses are associated to protection in seronegative partners of HIV infected individuals in Cambodia. J AIDS 2006; 42:412–419.
99. Ghys PD, Belec L, Diallo MO, Ettiegne-Traore V, Becquart P, Maurice C, et al. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Cote d'Ivoire. AIDS 2000; 14:2603–2608.
100. Buchacz K, Parekh BS, Padian NS, Van Der Straten A, Phillips S, Jonte J, Holmberg SD. HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV infected men. AIDS Res Hum Retrovir 2001; 17:1689–1693.
101. Farquhar C, VanCott T, Bosire R, Bermudez C, Mbori-Ngacha D, Lohman-Payne B, et al. Salivary human HIV-specific immunoglobulin A in HIV-1-exposed infants in Kenya. Clin Exp Immunol 2008; 153:37–43.
102. Sangster MY, Riberdy JM, Gonzalez M, Topham DJ, Baumgarth N, et al. An early CD4+ T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T–B interactions. J Exp Med 2003; 198:1011–1021.
103. Gärdby E, Wrammert J, Schön K, Ekman L, Leanderson T, et al. Strong differential regulation of serum and mucosal IgA responses as revealed in CD28-deficient mice using cholera toxin adjuvant. J Immunol 2003; 170:55–63.
104. Fayette J, Dubois B, Vandenabeele S, Bridon JM, Vanbervliet B, et al. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 1997; 185:1909–1918.
105. Clerici M, Barassi C, Devito C, Pastori C, Piconi S, Trabattoni D, et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 2002; 16:1731–1741.
106. Lopalco L, Longhi R, Ciccomascolo F, De Rossi A, Pelagi M, Andronico F, et al. Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies. AIDS Res Hum Retrovir 1993; 9:33–39.
107. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer FA, et al. Mucosal IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14:1917–1920.
108. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J AIDS 2002; 30:413–420.
109. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165:5170–5176.
110. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001; 166:6257–6626.
111. Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol 2003; 170:3799–3805.
112. Hieshima K, Kawasaki Y, Hanamoto H, Nakayama T, Nagakubo D, Kanamaru A, et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol 2004; 173:3668–3675.
113. Castelletti E, Lo Caputo S, Kuhn L, Borelli M, Gajardo J, Sinkala M, et al. The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection. PLoS ONE 2007; 2:e969, doi: 10.1371/journal.pone.0000969.
114. Buchacz K, Parekh BS, Padian NS, Van der Straten A, Phillips S, Jonte J, Holmberg SD. HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men. AIDS Res Hum Retrovir 2001; 17:1689–1693.
115. Dorrell L, Hessell AJ, Wang M, Whittle H, Sabally S, Rowland-Jones S, et al. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 2000; 14:1117–1122.
116. Jackson S, Prince S, Kulhavy R, Mestecky J. False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens. AIDS Res Hum Retrovir 2000; 16:595–602.
117. Wright PF, Kozlowski PA, Rybczyk GK, Goepfert P, Staats HF, VanCott TC, et al. Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retrovir 2002; 18:1291–1300.
118. Kutteh WH, Prince SJ, Hammond KR, Kutteh CC, Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol 1996; 104:538–542.
119. Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 2007; 262:44–58.
120. Becquart P, Hocini H, Levy M, Sepou A, Kazatchkine D, Belec L. Secretory antihuman immunodeficiency virus (HIV) antibodies in colostrums and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis 2000; 181:532–539.
121. Kuhn L, Trabattoni D, Kankasa C, Sinkala M, Lissoni F, Ghosh M, et al. HIV-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr 2006; 149:611–616.
122. Giavendoni LD, Velasquillo MC, Parodi LM, Hubbard GB, Hodora VL. Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus. J Virol 2000; 74:1648–1657.
123. Kittilil S, Chun T-W, Mori S, Liu M, McLaughlin C, et al. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis 2003; 187:1038–1045.
124. Bruunsgaart H, Pedersen C, Skinhøj P, Pedersen BK. Clinical progression of HIV infection: role of NK cells. Scad J Immunol 1997; 46:91–95.
125. Jennes W, Verheyden S, Demanet C, Adje-Toure CA, Vuylsteke B, et al. Resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006; 177:6588–6592.
126. Boulet S, Sharafi S, Simic N, Bruneau J, Routy J-P, et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008; 22:595–599.
127. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, Nguyen N, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109:4296–4305.
128. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429–434.
129. Boulet S, Kleyman M, Kim JY, Kamya P, Sharafi S, Simic N, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487–1491.
130. Chiu YL, Greene WC. Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol 2006; 27:291–297.
131. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, Trabattoni D, et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007; 195:960–964.
132. Oliva H, Montserrat P, Lopez A, Martinez-Navio J, Franco R, Miro' J, et al. APOBEC3G protein expression in blood resting and activated CD4+ and CD8+ T cells. Its effect on susceptibility to HIV infection and progression. CROI 2008; Boston, MA, USA; 3–6 February 2008, abstract 212.
133. Misse D, Yssel H, Trabattoni D, Oblet C, Lo Caputo S, Mazzotta F, et al. IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol 2007; 178:407–415.
134. Yang C, Li M, Limpakarnjanarat K, Young NL, Hodge T, Butera ST, et al. Polymorphisms in the CCR5 coding and noncoding regions among HIV type 1-exposed, persistently seronegative female sex-workers from Thailand. AIDS Res Hum Retrovir 2003; 19:661–665.
135. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HA, et al. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5Δ32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retrovir 2001; 17:719–734.
136. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997; 277:959–965.
137. Louisirirotchanakul S, Liu H, Roongpisuthipong A, Nakayama EE, Takebe Y, Shioda T, Wasi C. Genetic analysis of HIV-1 discordant couples in Thailand: association of CCR2-64I homozygosity with HIV-1-negative status. J Acquir Immune Defic Syndr 2002; 29:314–315.
138. Liu H, Hwangbo Y, Holte S, Lee J, Wang C, Kaupp N, et al. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 2004; 190:1055–1058.
139. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 1998; 279:389–393.
140. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349:236–240.
141. Mombo LE, Lu CY, Ossari S, Bedjabaga I, Sica L, Krishnamoorthy R, et al. Mannose-binding lectin alleles in sub-Saharan Africans and relation with susceptibility to infections. Genes Immun 2003; 4:362–367.
142. Wichukchinda N, Kitamura Y, Rojanawiwat A, Nakayama EE, Song H, Pathipvanich P, et al. The polymorphisms in DC-SIGNR affect susceptibility to HIV type 1 infection. AIDS Res Hum Retrovir 2007; 23:686–692.
143. de la Torre MS, Torres C, Nieto G, Vergara S, Carrero AJ, Macias J, et al. Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. J Infect Dis 2008; 197:405–410.
144. Ball TB, Ji HZ, Kimani J, McLaren P, Marlin C, Hill AVS, et al. Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS 2007; 21:1091–1101.
145. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434–1440.
146. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Med 2007; 8:1324–1336.
147. Kuhn L, Schramm DB, Donninger S, Meddows-Taylor S, Coovadia AH, Sherman GG, et al. African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine. AIDS 2007; 21:1753–1761.
148. Pilotti E, Elviri L, Vicenzi E, Bertazzoni U, Re MC, Allibardi S, et al. Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood 2007; 109:1850–1856.
149. Hardie RA, Luo M, Bruneau B, Knight E, Nagelkerke NJ, Kimani J, et al. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS 2008; 22:807–816.
150. MacDonald KS, Embree J, Njenga S, Nagelkerke NJD, Ngatia I, Mohammed Z, et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 1998; 177:551–556.
151. Kanari Y, Clerici M, Abe H, Kawabata H, Trabattoni D, Lo Caputo S, et al. Genotypes at chromosome 22q12–13 are associated with HIV-1-exposed but uninfected status in Italians. AIDS 2005; 19:1015–1024.
152. Cole AM, Cole AL. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59:27–34.
153. Mackewicz CE, Yuan J, Tran P, Diaz L, Mack E, Selsted ME, Levy JA. α-Defensins can have anti-HIV activity but are not CD8+ cell anti-HIV factors. AIDS 2003; 17:F23–F32.
154. Kulkarni PS, Butera ST, Duerr AC. Resistance to HIV-1 infection: lessons learnt from studies of highly exposed persistently serogenative (HEPS) individuals. AIDS Rev 2003; 5:87–103.
155. Soriano A, Martinez C, Garcia F, Plana M, Palou E, Lejeune M, et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3′A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 2002; 186:922–931.
156. Malik S, Arias M, Di Flumeri C, Garcia LF, Schurr E. Absence of association between mannose-binding lectin gene polymorphisms and HIV-1 infection in a Colombian population. Immunogenetics 2003; 55:49–52.
157. Marquet S, Sanchez FO, Arias M, Rodriguez J, Paris SC, Skamene E, et al. Variants of the human NRAMP1 gene and altered human immunodeficiency virus infection susceptibility. J Infect Dis 1999; 180:1521–1525.
158. Chesebro B, Miyazawa M, Britt WJ. Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol 1990; 8:477–499.
159. Miyazawa M. Host genes that influence immune and nonimmune resistance mechanisms against retrovrial infections. Recent Res Dev Virol 2004; 6:105–118, 2004.
160. Miyazawa M, Tsuji-Kawahara S, Kanari Y. Host genetic factors that control immune responses to retrovirus infections. Vaccine 2008. doi: 10.1016/j.vaccine.2008.01.004.
161. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535–551.
162. Carrington M, Bontrop RE. Effects of MHC class I on HIV/SIV disease in primates. AIDS 2002; 16(Suppl 4):S105–S114.
163. Miyazawa M, Fujisawa R, Ishihara C, Takei YA, Shimizu T, Uenishi H, et al. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. J Immunol 1995; 155:748–758.
164. Kawabata H, Niwa A, Tsuji-Kawahara S, Uenishi H, Iwanami N, Matsukuma H, et al. Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease. Int Immunol 2006; 18:183–198.
165. Iwanami N, Niwa A, Yasutomi Y, Tabata N, Miyazawa M. Role of natural killer cells in resistance against Friend retrovirus-induced leukemia. J Virol 2001; 75:3152–3163.
166. Takeda E, Tsuji-Kawahara S, Sakamoto1 M, Langlois M-A, Neuberger MS, Rada C, et al. Mouse APOBEC3 restricts Friend leukemia virus infection and pathogenesis in vivo. J Virol 2008. [Epub ahead of print].
167. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, et al. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 2008; 321:1343–1346.
168. Clerici M, Shearer GM. Is HIV infection associated with a TH1→ TH2 switch? Immunol Today 1993; 14:107–111.
169. Salk J, Bretscher PA, Salk PL, Clerici M, Shearer GM. A strategy for prophylactic vaccination against HIV. Science 1993; 260:1270–1272.
170. Lehner T, Wang YF, Cranage M, Bergmeier LA, Mitchell E, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996; 2:767–775.
© 2009 Lippincott Williams & Wilkins, Inc.